UNCY
Unicycive Therapeutics, Inc.
NasdaqCMUSDEQUITY
Healthcare
DELAYED
Sell
-51/100
Last price
4.21
▼ 0.02 (0.47%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
4.18
Prev close
4.23
Day high
4.22
Day low
4.08
Volume
265.95K
Market cap
$115.32M
P/E (TTM)
—
52W range
3.93 – 8.74
Day trading desk
Gap from prior close
-1.24%
Prior close 4.23
VWAP
4.16
+1.24% from price
Relative volume
0.31×
Quiet session
Session range
3.43%
4.08 – 4.22
Position in range
93%
Near session high
ATR (14D)
0.22
5.26% of price
Prior day high
4.29
PDH
Prior day low
4.15
PDL
Bid / ask spread
—
Quote not published
Session volume
260.97K
Avg 849.93K
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-10.33%
-12.1%
1M
-16.30%
-17.7%
3M
-19.96%
-23.2%
6M
-34.73%
-49.6%
YTD
-27.04%
-40.9%
1Y
-8.48%
-24.1%
3Y
-54.24%
-135.9%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on UNCY open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
629.53K
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Aug 25, 25 | AGGARWAL GAURAV Director |
— | 652.90K | — | Indirect |
| Feb 18, 25 | AGGARWAL GAURAV Director |
— | 1.40M | — | Indirect |
| Oct 9, 24 | AGGARWAL GAURAV Director |
— | 5.50M | — | Indirect |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
AGGARWAL GAURAV |
Director | — | Conversion of Exercise of derivative security |
Fundamentals
Market cap$115.32M
Enterprise value$57.07M
Revenue (TTM)—
Gross profit—
EBITDA$-33.09M
Net income$-35.22M
EPS (TTM)$-1.72
Free cash flow$-12.72M
Total cash$61.42M
Total debt$671.00K
Book value / share$1.91
Shares outstanding27.39M
Float27.21M
Short % of float15.44%
Dividend yield0.00%
Beta (5Y)1.82
Valuation & profitability ratios
Trailing P/E—
Forward P/E2.50
PEG ratio—
Price / sales—
Price / book2.20
EV / revenue—
EV / EBITDA-1.73
Gross margin0.00%
Operating margin0.00%
Profit margin0.00%
Return on equity-101.07%
Return on assets-40.59%
Debt / equity1.26
Current ratio3.81
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $675.00K | $951.00K | — |
| Operating revenue | $0 | $0 | $675.00K | $951.00K | — |
| Research & development | $9.12M | $20.01M | $12.90M | $12.44M | -54.4% |
| Selling, general & admin | $20.40M | $12.10M | $8.55M | $6.57M | +68.5% |
| Total operating expense | $29.52M | $32.12M | $21.45M | $19.00M | -8.1% |
| Operating income | -$29.52M | -$32.12M | -$20.77M | -$18.05M | +8.1% |
| Net interest income | $941.00K | $1.19M | $533.00K | -$6.00K | -20.9% |
| Pre-tax income | -$26.55M | -$36.73M | -$30.54M | -$18.06M | +27.7% |
| Net income | -$26.55M | -$36.73M | -$30.54M | -$18.06M | +27.7% |
| Net income to common | -$26.55M | -$37.82M | -$31.41M | -$18.06M | +29.8% |
| Basic EPS | -1.67 | -5.65 | -12.80 | -12.00 | +70.4% |
| Diluted EPS | -1.67 | -5.65 | -12.80 | -12.00 | +70.4% |
| EBIT | -$26.48M | -$36.66M | -$30.46M | -$18.05M | +27.8% |
| EBITDA | -$25.91M | -$36.23M | -$30.18M | -$17.89M | +28.5% |
| Basic shares | 15.89M | 6.70M | 2.45M | 1.51M | +137.2% |
| Diluted shares | 15.89M | 6.70M | 2.45M | 1.51M | +137.2% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $29.20M | $26.14M | $9.70M | $455.00K | +11.7% |
| Cash & short-term investments | $41.27M | $26.14M | $9.70M | $455.00K | +57.9% |
| Total current assets | $48.96M | $30.95M | $13.40M | $2.64M | +58.2% |
| Property, plant & equipment | $174.00K | $720.00K | $792.00K | $174.00K | -75.8% |
| Total assets | $49.13M | $31.67M | $14.19M | $2.82M | +55.2% |
| Total current liabilities | $18.94M | $24.12M | $17.53M | $3.28M | -21.5% |
| Current debt | $82.00K | $92.00K | $18.00K | $46.00K | -10.9% |
| Total debt | $199.00K | $773.00K | $811.00K | $201.00K | -74.3% |
| Total liabilities | $18.94M | $24.24M | $18.00M | $3.28M | -21.9% |
| Retained earnings | -$127.83M | -$101.27M | -$64.54M | -$34.00M | -26.2% |
| Shareholder equity | $30.20M | $7.43M | -$3.81M | -$466.00K | +306.4% |
| Working capital | $30.02M | $6.83M | -$4.13M | -$640.00K | +339.7% |
| Net tangible assets | $30.20M | $7.43M | -$3.81M | -$466.00K | +306.4% |
| Shares issued | 22.11M | 11.38M | 3.48M | 1.52M | +94.3% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$26.55M | -$36.73M | -$30.54M | -$18.06M | +27.7% |
| Depreciation & amortisation | $572.00K | $428.00K | $284.00K | $161.00K | +33.6% |
| Stock-based compensation | $2.64M | $2.35M | $1.77M | $1.05M | +12.4% |
| Change in working capital | -$5.95M | -$427.00K | -$93.00K | $1.18M | -1,294.4% |
| Operating cash flow | -$31.32M | -$28.57M | -$18.28M | -$15.65M | -9.6% |
| Capital expenditure | -$24.00K | -$72.00K | -$12.00K | -$2.00K | +66.7% |
| Investing cash flow | -$12.10M | -$72.00K | -$12.00K | -$2.00K | -16,698.6% |
| Dividends paid | $0 | -$1.09M | $0 | — | +100.0% |
| Financing cash flow | $46.47M | $45.09M | $27.54M | -$471.00K | +3.1% |
| Free cash flow | -$31.34M | -$28.65M | -$18.30M | -$15.65M | -9.4% |
| End cash position | $29.20M | $26.14M | $9.70M | $455.00K | +11.7% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | $0 | — | — |
| Operating revenue | $0 | $0 | $0 | $0 | $0 | — | — |
| Research & development | $2.79M | $1.61M | $2.25M | $2.96M | $1.75M | — | +73.5% |
| Selling, general & admin | $7.35M | $6.83M | $4.97M | $4.38M | $5.21M | — | +7.6% |
| Total operating expense | $10.14M | $8.44M | $7.22M | $7.34M | $6.96M | — | +20.2% |
| Operating income | -$10.14M | -$8.44M | -$7.22M | -$7.34M | -$6.96M | — | -20.2% |
| Net interest income | $441.00K | $394.00K | $324.00K | $264.00K | $142.00K | — | +11.9% |
| Pre-tax income | -$1.72M | -$12.82M | -$14.67M | -$6.01M | -$6.45M | — | +86.6% |
| Net income | -$1.72M | -$12.82M | -$14.67M | -$6.01M | -$6.45M | — | +86.6% |
| Net income to common | -$1.72M | -$12.82M | -$14.67M | -$6.01M | -$6.45M | — | +86.6% |
| Basic EPS | -0.06 | -0.54 | — | -0.33 | -0.52 | 0.00 | +88.9% |
| Diluted EPS | -0.06 | -0.54 | — | -0.33 | -0.52 | -0.50 | +88.9% |
| EBIT | -$1.72M | -$12.82M | -$14.64M | -$6.00M | -$6.43M | — | +86.6% |
| EBITDA | -$1.57M | -$12.61M | -$14.49M | -$5.85M | -$6.30M | — | +87.5% |
| Basic shares | 26.92M | 23.91M | — | 18.07M | 12.30M | 11.68M | +12.6% |
| Diluted shares | 26.92M | 23.91M | — | 18.07M | 12.30M | 12.38M | +12.6% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $44.19M | $37.37M | $29.20M | $42.70M | $22.33M | +18.2% |
| Cash & short-term investments | $61.42M | $54.59M | $41.27M | $42.70M | $22.33M | +12.5% |
| Total current assets | $71.32M | $63.55M | $48.96M | $50.29M | $29.53M | +12.2% |
| Property, plant & equipment | $709.00K | $861.00K | $174.00K | $324.00K | $469.00K | -17.7% |
| Total assets | $72.03M | $64.41M | $49.13M | $50.61M | $30.00M | +11.8% |
| Total current liabilities | $18.70M | $26.48M | $18.94M | $13.13M | $13.57M | -29.4% |
| Current debt | $67.00K | $126.00K | $82.00K | $240.00K | $67.00K | -46.8% |
| Total debt | $738.00K | $941.00K | $199.00K | $505.00K | $476.00K | -21.6% |
| Total liabilities | $18.76M | $26.70M | $18.94M | $13.13M | $13.57M | -29.7% |
| Retained earnings | -$142.37M | -$140.65M | -$127.83M | -$113.16M | -$107.15M | -1.2% |
| Shareholder equity | $53.27M | $37.70M | $30.20M | $37.48M | $16.43M | +41.3% |
| Working capital | $52.62M | $37.06M | $30.02M | $37.16M | $15.96M | +42.0% |
| Net tangible assets | $53.27M | $37.70M | $30.20M | $37.48M | $16.43M | +41.3% |
| Shares issued | 27.86M | 25.24M | 22.11M | 20.85M | 14.11M | +10.4% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Net income | -$1.72M | -$12.82M | -$14.67M | -$6.01M | -$6.45M | — | +86.6% |
| Depreciation & amortisation | $151.00K | $211.00K | $151.00K | $148.00K | $138.00K | — | -28.4% |
| Stock-based compensation | $2.88M | $754.00K | $777.00K | $730.00K | $571.00K | — | +281.6% |
| Change in working capital | -$900.00K | $807.00K | -$2.06M | $237.00K | -$2.31M | — | -211.5% |
| Operating cash flow | -$7.60M | -$6.24M | -$8.03M | -$5.96M | -$8.42M | — | -21.8% |
| Capital expenditure | — | -$8.00K | — | -$2.00K | -$6.00K | -$16.00K | — |
| Investing cash flow | -$23.00K | -$5.16M | -$12.07M | -$2.00K | -$6.00K | — | +99.6% |
| Dividends paid | — | — | $0 | $0 | — | — | — |
| Financing cash flow | $14.44M | $19.57M | $6.61M | $26.33M | $10.98M | — | -26.2% |
| Free cash flow | -$7.60M | -$6.25M | -$8.03M | -$5.96M | -$8.43M | — | -21.7% |
| End cash position | $44.19M | $37.37M | $29.20M | $42.70M | $22.33M | — | +18.2% |
Options analytics
Put / call volume
0.10
Call-heavy session
Put / call open interest
3.63
Positioning, not flow
Max pain
5.00
+18.8% from spot
ATM implied vol
95.3%
Nearest strike to spot
Skew (10% OTM)
+31.3%
Puts bid over calls
Call volume
179
Contracts, this expiry
Put volume
18
Contracts, this expiry
Heaviest call OI
5.00
508 contracts
Heaviest put OI
5.00
1.98K contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.33 | -0.06 | +81.7% |
| Mar 2026 | -0.48 | — | — |
| Dec 2025 | -0.46 | -0.82 | -80.0% |
| Sep 2025 | -0.53 | -0.33 | +37.7% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.35 | 9 | $0 | 0.0% |
| Next quarter | -0.32 | 9 | $366.67K | 0.0% |
| Current year | -1.27 | 9 | $1.37M | 0.0% |
| Next year | 1.69 | 8 | $149.50M | +10,812.6% |
Analyst targets & ownership
Mean target$28.40
High target$42.00
Low target$13.00
Implied upside574.58%
Analyst count10
ConsensusSTRONG BUY
Strong buy / Buy2 / 8
Hold0
Sell / Strong sell0 / 0
Held by insiders2.26%
Held by institutions42.26%
Institutions holding111
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
4.48
-6.01% from price
SMA 20
4.71
-10.56% from price
SMA 50
5.04
-16.47% from price
SMA 100
5.82
-27.65% from price
SMA 200
6.28
-32.99% from price
EMA 12
4.49
-6.21% from price
EMA 26
4.74
-11.18% from price
EMA 50
5.06
-16.73% from price
RSI (14)
31.6
Neutral
MACD (12,26,9)
-0.25
Hist -0.05
ATR (14)
0.22
5.26% of price
Realised vol 30D
46.2%
Annualised
Bollinger upper
5.35
20, 2σ
Bollinger lower
4.07
20, 2σ
50 / 200 cross
Death
5.04 vs 6.28
Trend bias
Below 200
-32.99%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
1.04
More volatile than market
Correlation to SPY
0.17
Largely independent
Realised vol 30D
46.2%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-51.1%
Peak to trough
Max drawdown 5Y
-92.3%
Peak to trough
ATR 14
0.22
5.26% of price
Beta (reported)
1.82
5Y monthly, from filing
Short interest
Shares short
4.20M
Prior 4.15M
Change vs prior
+1.2%
Shorts adding
% of float
15.44%
Elevated
% of shares out
15.09%
Against total outstanding
Days to cover
5.3
Crowded exit
Float
27.21M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 29, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Aug 20, 26 | Benchmark | MAINTAINED | Speculative Buy | Speculative Buy |
| Aug 13, 26 | Guggenheim | MAINTAINED | Buy | Buy |
| Aug 13, 26 | B. Riley Securities | MAINTAINED | Buy | Buy |
| Jul 1, 26 | Benchmark | MAINTAINED | Speculative Buy | Speculative Buy |
| Jul 1, 26 | Noble Capital Markets | MAINTAINED | Outperform | Outperform |
| Jun 30, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Jun 30, 26 | B. Riley Securities | MAINTAINED | Buy | Buy |
| Jun 2, 26 | Benchmark | MAINTAINED | Speculative Buy | Speculative Buy |
| May 13, 26 | Guggenheim | MAINTAINED | Buy | Buy |
| Apr 6, 26 | Benchmark | MAINTAINED | Speculative Buy | Speculative Buy |
| Apr 2, 26 | Guggenheim | MAINTAINED | Buy | Buy |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio—
Ex-dividend date—
Next pay date—
Last split1:10
Split dateJun 20, 2025
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-09-29
Corporate Changes & Voting Matters
8-K · 2026-09-28
Periodic Financial Reports
10-Q · 2026-08-12
Corporate Changes & Voting Matters
8-K · 2026-07-02
Proxy Statements
DEFA14A · 2026-06-22
A correspondence can be sent as a document with another submission type or can be sent as a separate submission
CORRESP · 2026-06-11
Corporate Changes & Voting Matters
8-K · 2026-06-05
Periodic Financial Reports
10-Q · 2026-05-12
Headlines
Unicycive Therapeutics Appoints Meredith Manning to Board of Directors
GlobeNewswire · 6d ago
Unicycive Therapeutics Announces Resubmission of New Drug Application for Oxylanthanum Carbonate
GlobeNewswire · 8d ago
Unicycive Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference
GlobeNewswire · 36d ago
B. Riley Adjusts Price Target on Unicycive Therapeutics to $20 From $22, Maintains Buy Rating
MT Newswires · 55d ago
Unicycive Therapeutics shares rise after second-quarter loss beats forecasts
InvestorsHub · 56d ago
Unicycive Therapeutics Announces Second Quarter 2026 Financial Results and Provides Business Update
GlobeNewswire · 56d ago
Hyperphosphatemia Market Set for Robust Growth During the Forecast Period (2026-2036), Driven by Novel Therapeutics and Rising CKD Burden | DelveInsight
PR Newswire · 63d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.